atezolizumab + chemotherapy

Atezolizumab + chemotherapy is a combination regimen consisting of **atezolizumab**, a humanized monoclonal antibody targeting programmed cell death ligand 1 (**PD-L1**), combined with platinum-based chemotherapeutic agents (typically carboplatin and etoposide or paclitaxel, and sometimes bevacizumab or paclitaxel protein-bound)[2][3][5][7]. Atezolizumab blocks PD-L1 interactions with PD-1 and B7.1 receptors, enhancing anti-tumor immune responses. Combination with chemotherapy exploits synergistic effects: chemotherapy induces cancer cell death and may increase antigen presentation, while atezolizumab augments immune-mediated elimination of tumor cells. This regimen is FDA-approved for first-line treatment of **extensive-stage small cell lung cancer (SCLC)** and **metastatic non-squamous non-small cell lung cancer (NSCLC)** (without EGFR or ALK genomic aberrations), and is under investigation or used for other malignancies such as hepatocellular carcinoma and melanoma[2][3][5][7].

Brand names

Tecentriq

Other names

atezolizumab + carboplatin + etoposideatezolizumab + paclitaxel + carboplatinatezolizumab + paclitaxel protein-bound + carboplatinatezolizumab + bevacizumab + carboplatin + paclitaxel